Helpful Resources

Indications and Usage for Apidra® (insulin glulisine injection)

Prescription Apidra is a fast (rapid) acting insulin used for adults and children with diabetes mellitus to control high blood sugar. It is not known if APIDRA is safe or effective in children less than 4 years of age with type 1 diabetes or in children with type 2 diabetes.

When used as a mealtime insulin, Apidra should be given within 15 minutes before or within 20 minutes after starting a meal.

Apidra may be infused subcutaneously by external insulin infusion pumps.

Do not use Apidra if you have low blood sugar reaction or if you are allergic to insulin glulisine or any of the ingredients in Apidra.

Do not share needles, insulin pens or syringes with others even if the needle is changed. Do NOT reuse needles. You may give other people a serious infection, or get a serious infection from them.

Before starting Apidra, tell your doctor about all your medical conditions, including if you have liver or kidney problems, if you are pregnant or planning to become pregnant or if you are breastfeeding or planning to breastfeed.

Heart failure can occur if you are taking insulin together with pills called TZDs (thiazolidinediones), even if you never had heart failure or other heart problems. If you have heart failure, it may get worse while you take TZDs with Apidra. Your treatment with TZDs and Apidra may need to be changed or stopped by your doctor if you have new or worsening heart failure. Tell your doctor if you have new or worsening symptoms, including:

Shortness of breath

Sudden weight gain

Swelling of your ankles or feet

Tell your doctor about all medications you take, including OTC medicines, vitamins, supplements, and herbal supplements.

When used a mealtime insulin, Apidra should be taken within 15 minutes before a meal or within 20 minutes after starting a meal. Test your blood sugar levels as directed by your doctor when using Apidra. Do not change your dose or type of insulin without talking to your doctor. Any change of insulin should be made cautiously and only under medical supervision.

Check your insulin label to verify that you have the correct insulin before each injection. Use Apidra only if the solution is clear and colorless with no particles visible.

While using Apidra, do not drive or operate heavy machinery until you know how Apidra affects you. Do not drink alcohol or use medicines that contain alcohol.

Apidra may cause serious side effects that can lead to death, including:

The most common side effects of APIDRA include: low blood sugar (hypoglycemia), weight gain, itching, rash, swelling, allergic reactions including injection site reactions, skin thickening or pits at the injection site (lipodystrophy)

Apidra SoloSTAR is a disposable prefilled insulin pen. Please talk to your healthcare provider about proper injection techniques and follow instructions in the Instruction Leaflet that accompanies the pen.

Important Safety Information for Apidra® (insulin glulisine injection) when used in a pump

Replace the infusion sets (reservoir, tubing, and catheter), and the Apidra in the reservoir at least every 48 hours and select a new infusion site. Do not mix or dilute Apidra when used in the pump.
Failure of your insulin pump or infusion set or degradation of the insulin in the pump can cause hyperglycemia and ketoacidosis. Always carry an alternate form of insulin administration in the case of pump failure.

Click here for Full Prescribing Information for Apidra.Click here for information on Sharps Medical Waste Disposal. Click here to learn more about Sanofi's commitment to fighting counterfeit drugs.

If you are a patient experiencing problems with a Sanofi US product, please contact Sanofi US at 1-800-633-1610.

The health information contained herein is provided for general educational purposes only. Your healthcare professional is the single best source of information regarding your health. Please consult your healthcare professional if you have any questions about your health or treatment.

*

back to top ▲

*Eligibility Restrictions & Offer Terms:

Insulins Valyou Savings Program:

Sanofi insulins included in this program are: ADMELOG® (insulin lispro injection) 100 Units/mL, TOUJEO® (insulin glargine injection) 300 Units/mL, LANTUS® (insulin glargine injection) 100 Units/mL and APIDRA® (insulin glulisine injection) 100 Units/mL. This offer is not valid for prescriptions covered by or submitted for reimbursement under Medicare, Medicaid, VA, DOD, TRICARE, similar federal or state programs, including any state pharmaceutical programs, or commercial / private insurance. Only people without prescription medication insurance can apply for this offer. Void where prohibited by law. For the duration of the program, eligible patients will pay $99 for up to 10 vials or packs of pens per fill. Offer is valid for one fill per month. To pay $99 per month, you must fill all your Sanofi Insulin prescriptions at the same time, together each month. Not valid for SOLIQUA 100/33 (insulin glargine and lixisenatide injection) 100 Units/mL and 33 mcg/mL or Toujeo Max SoloStar pen. When using the Insulins Valyou Savings Card, prices are guaranteed for 12 consecutive monthly fills. The Insulins Valyou Savings Program applies to the cost of medication. There are other relevant costs associated with overall treatment.

Sanofi Copay Program:

This offer is not valid for prescriptions covered by or submitted for reimbursement under Medicare, Medicaid, VA, DOD, TRICARE, or similar federal or state programs including any state pharmaceutical assistance program. Important to note that if you have an Affordable Care (Health Care Exchange) plan, you may still be qualified to receive and use this savings card. Please note: the Federal Employees Health Benefits (FEHB) Program is not a federal or state government health care program for purposes of the savings program. Void where prohibited by law.

Apidra: $0 copay with maximum savings up to $100 per pack up to 1 pack per fill.

Savings may vary depending on patients’ out-of-pocket costs. Upon registration, patients receive all program details. Sanofi US reserves the right to change the maximum cap amount, rescind, revoke or amend these programs without notice.

You are about to leave a Sanofi U.S. website

Please note: By clicking on this link, you will be leaving this Sanofi US website and going to another, entirely independent website. Sanofi US provides these links as a service to their website visitors and users; however, the company takes no responsibility for the information on any website but their own.

Click the “Continue” button below to go to the page you requested or click “Cancel” to remain on this page.